Milan, 1 April (beraking latest news Salute) – High protection even after 6 months from the shield injection. A new updated analysis “shows that the vaccine” from Pfizer and BioNTech “has an efficacy of 91.3% against Covid-19, measured from 7 days to 6 months after the second dose”. This was communicated by the two companies, reporting the results of the analysis conducted on the 46,307 participants in the study (more than 12 thousand received the vaccine at least 6 months ago).
The examination of 927 confirmed symptomatic cases of Covid confirms “the high efficacy and the absence of serious safety problems up to six months after the second dose in the updated analysis of the historical study on the vaccine“. Vaccine which was found to be “100% effective in the prevention of severe diseases as defined by the US Centers for Disease Control and Prevention and 95.3% effective in the prevention of severe Covid as defined by the US FDA”.
“These data – commented Pfizer’s president and CEO, Albert Bourla – confirm the favorable efficacy and safety profile of our vaccine and allow us to submit a Biologics License Application to the United States FDA”, which is the application for approval. of an organic product. “The high vaccine efficacy observed up to six months after a second dose and against the variant prevalent in South Africa provides further confidence in the overall efficacy of our vaccine.”
“This is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a long-term follow-up,” added Ugur Sahin, CEO and co-founder of BioNTech. “These data also provide the first clinical results that a vaccine can effectively protect against variants currently in circulation, a crucial factor in achieving herd immunity and ending this pandemic for the global population.”
The reference is to the data observed in South Africa, where variant B.1.351 is prevalent and 800 study participants were enrolled: 9 cases of Covid observed, all in the placebo group, indicating a vaccine efficacy of 100%. In an exploratory analysis, the 9 strains were sequenced and 6 were confirmed to be variant. These data support previous findings from immunogenicity studies showing that the mRna vaccine induced a “robust neutralizing antibody response” to the South African variant and, “although inferior to the ‘wild-type’ strain, does not appear to affect the observed high efficacy. against this variant “.
COPYRIGHT today © breaking latest news